Mosanna Therapeutics, a biotech company rethinking treatment of obstructive sleep apnea (OSA), announced the close of $80 million in Series A funding. The company is developing an easy-to-use nighttime nasal spray to treat obstructive sleep apnea that will help restore the body's natural airway control.

The financing was led by Pivotal bioVenture Partners and EQT Life Sciences, along with Forbion, Broadview Ventures and Norwest as co-lead investors. Returning investors included founding investor Forty51 Ventures, as well as Supermoon Capital and High-Tech Grunderfonds (HTGF).